Chemotherapy-induced toxicities, such as neuropathy, are accepted as a consequence of some effective therapies. However, neuropathy is also a primary dose-limiting complication of many compounds. Early recognition and management of symptoms have become crucial to any neurologist participating in the care of these complicated patients. Preventative strategies to limit neurotoxicity have been long sought but remain limited. Dr. Louis Weimer of Columbia University details the well-known and emerging medications associated with chemotherapy-induced neuropathy, such as bortezomib, eribulin mesylate, pomalidomide, carfilzomib, and ixabepilone.